Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Dr Lal PathLabs to acquire 70 percent stake in Amins Pathology Referral Laboratory

      Dr Lal PathLabs to acquire 70 percent stake in Amins Pathology Referral Laboratory

      Medical Dialogues Bureau3 Oct 2019 4:34 PM IST
      New Delhi: Diagnostic chain Dr Lal PathLabs said the board of its arm PathLabs Unifiers has approved acquisition of 70 per cent stake in Amins...
      Roche presents positive Phase III results for Tecentriq

      Roche presents positive Phase III results for Tecentriq

      Medical Dialogues Bureau3 Oct 2019 4:17 PM IST
      Roche has recently presented positive results from the Phase III IMvigor130 study evaluating Tecentriq® (atezolizumab) plus platinum-based...
      Sreeji Gopinathan joins Lupin as Chief Information Officer

      Sreeji Gopinathan joins Lupin as Chief Information Officer

      Medical Dialogues Bureau3 Oct 2019 4:03 PM IST
      Mumbai, October 03, 2019: Pharma major Lupin Limited announced today the appointment of Sreeji Gopinathan as Chief Information Officer (CIO). He will...
      Biocon, Mylan launch insulin biosimilar Semglee in Australia

      Biocon, Mylan launch insulin biosimilar Semglee in Australia

      Medical Dialogues Bureau3 Oct 2019 3:51 PM IST
      New Delhi: Biotechnology major Biocon and pharmaceutical company Mylan N V on Thursday announced the launch of their insulin biosimilar Semglee,...
      JnJ to pay $20.4 million to settle opioid lawsuits with two Ohio counties

      JnJ to pay $20.4 million to settle opioid lawsuits with two Ohio counties

      Medical Dialogues Bureau3 Oct 2019 9:28 AM IST
      Johnson & Johnson said on Tuesday it will pay $20.4 million to settle claims by two Ohio counties in a lawsuit that accused the drugmaker of...
      AstraZeneca prostate cancer drug Lynparza shows promise

      AstraZeneca prostate cancer drug Lynparza shows promise

      Medical Dialogues Bureau2 Oct 2019 9:35 AM IST
      Analysts see AstraZeneca and Merck's Lynparza leading the PARP inhibitor class with an average sales estimate of $3.1 billion for 2023. Rival...
      Bayer to improve disease diagnosis, drug design via use of AI

      Bayer to improve disease diagnosis, drug design via use of AI

      Medical Dialogues Bureau2 Oct 2019 9:32 AM IST
      Germany's Bayer has been testing how the technology can help diagnose complex or rare conditions, hasten drug development and more.New Delhi:...
      Bangladesh BANS import of raw materials, production, sale of RANITIDINE over cancer fears

      Bangladesh BANS import of raw materials, production, sale of RANITIDINE over cancer fears

      Medical Dialogues Bureau2 Oct 2019 9:15 AM IST
      Drug manufacturers across the world have begun recalling the widely taken heartburn drug, which is sold under the trade name Zantac among others,...
      Lupin unveils generic version of Viagra in US

      Lupin unveils generic version of Viagra in US

      Medical Dialogues Bureau1 Oct 2019 1:32 PM IST
      Lupin’s Sildenafil Tablets USP, 25 mg, 50 mg, and 100 mg, is the generic version of Pfizer Inc’s Viagra Tablets, 25 mg, 50 mg, and 100 mg. Mumbai:...
      PIL against Health Ministry notifying 8 medical devices as DRUGS, Delhi HC seeks Centre reply

      PIL against Health Ministry notifying 8 medical devices as DRUGS, Delhi HC seeks Centre reply

      Medical Dialogues Bureau30 Sept 2019 5:54 PM IST
      It was submitted that notifying blood monitoring devices, digital thermometers, nebulizers and glucometers as DRUGS will result in a substantial hike...
      Cipla gets 12 USFDA observations for Goa facility

      Cipla gets 12 USFDA observations for Goa facility

      Medical Dialogues Bureau30 Sept 2019 3:15 PM IST
      "The United States Food and Drug Administration (USFDA) conducted a cGMP inspection at our Goa manufacturing facility from September 16-27, 2019,"...
      Glenmark Pharma to raise Rs 1413 crore via debt securities

      Glenmark Pharma to raise Rs 1413 crore via debt securities

      Medical Dialogues Bureau30 Sept 2019 3:03 PM IST
      According to the proposal, Glenmark Pharma plans to raise up to $ 200 million in Indian and/or international market through bonds, debentures or other...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok